Business
CDX Antibody Update
CDX Antibody Update.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2105U\n Hemogenyx Pharmaceuticals PLC\n 01 April 2021\n \n \n \n \n 1 April 2021\n \n \n \n \n \n Hemogenyx Pharmaceuticals plc\n \n \n (\"Hemogenyx Pharmaceuticals\" or the \"Company\")\n \n \n \n \n \n CDX Antibody Update\n \n \n \n \n \n \n Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to issue an update on negotiations regarding the future development of its leading product candidate CDX bispecific antibody (\"CDX\") for the treatment of acute myeloid leukemia (\"AML\"). \n \n \n \n \n \n On 13 January 2021, the Company \n \n \n announced\n \n \n the completion of development of CDX with a global pharmaceutical company \n (\"GlobalCo\"). \n With the development phase of the agreement completed, GlobalCo or the Company may exercise an option to license the other party's intellectual property necessary to exploit the CDX antibody on an exclusive worldwide basis. \n \n \n \n \n \n The Company is pleased to announce that negotiations have commenced with GlobalCo regarding the form of licensing and further development of CDX toward clinical trials. The results of these negotiations and the outline of the path toward the further development of CDX will be announced upon their completion.\n \n \n \n \n \n At the same time, the Company is progressing in the development of \n its leading product candidate Chimeric Antigen Receptor (\"CAR\") T-cells (\"HEMO-CAR-T\"). As announced on \n \n \n 3 March 2021\n \n \n , the Company has engaged a highly experienced consultant in the field of manufacturing and quality control operations and has initiated the process of engaging contract manufacturing organizations (\"CMOs\") for product development and manufacturing to support Phase I clinical trials of HEMO-CAR-T. Discussions and negotiations with CMOs continue and the Directors are confident that the Company is poised to move ahead toward clinical trials with an outstanding team, including the University of Pennsylvania, with which the Company \n \n \n has entered into a Master Translational Research Services Agreement\n \n \n , the goal of which is to advance HEMO-CAR-T toward clinical trials.\n \n \n \n \n \n Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmace...